inhibikase.com/news/press-r...
"We are grateful for the expeditious review by the FDA of our response to the Clinical Hold on IkT-148009 in PD," stated Milton H. Werner, Ph.D., President and Chief Executive Officer of Inhibikase Therapeutics. "We believe that we now have clarity on the FDA's expectations as we move forward in the 201 clinical trial for IkT-148009. We are now working to re-open clinical trial sites and initiate screening and enrollment of patients for the trial following agreed upon updates to the Protocol and Informed Consent form. We anticipate completing these restart tasks by the end of the first quarter."
Today we announced that the US FDA has cleared IND applications for 4dpharmaplc’s LiveBiotherapeutics MRx0005 and MRx0029, Phase I
Annovis Bio Announces Approval for EU Clinical Trial Sites for the Phase 3 Study of Buntanetap for the Treatment of Parkinson's Disease
